Author

Rachel Sachs

  • FDA

    How Can the US Address Coronavirus Drug Shortages?

    With the sudden spike in hospitalized patients with COVID-19 symptoms, physicians are using these drugs faster than manufacturers are making them.

    How Can the US Address Coronavirus Drug Shortages?

    Pile of colorful pills in blister packs
  • FDA

    What Does It Mean That Oracle is Partnering with the Trump Administration to Study Unproven COVID-19 Drugs?

    Cross-posted from Written Description, where it originally appeared on March 30, 2020.  By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob Sherkow One of the dizzying stream of innovation and health law stories to emerge last week is Oracle’s partnership with…

    What Does It Mean That Oracle is Partnering with the Trump Administration to Study Unproven COVID-19 Drugs?

    pills
  • Medicare/Medicaid

    CMS Abandonment of Outcomes-Based Payment Deal with Novartis is a Missed Opportunity

    By Rachel Sachs Earlier this week, Politico broke the news that the Centers for Medicare and Medicaid Services (CMS) had withdrawn its outcomes-based payment deal for Novartis’ CAR-T therapy, Kymriah, without public acknowledgement. The Food…

    CMS Abandonment of Outcomes-Based Payment Deal with Novartis is a Missed Opportunity

    Image of Novatis building
  • Health Care Finance

    Massachusetts Wants To Drive Down Medicaid Drug Costs: Why Is The Administration So Nervous?

    This new post by Nicholas Bagley and Rachel Sachs appears on the Health Affairs Blog.  Although drug formularies are ubiquitous in Medicare and the private insurance market, they’re absent in Medicaid. By law, state Medicaid programs that…

    Massachusetts Wants To Drive Down Medicaid Drug Costs: Why Is The Administration So Nervous?

  • FDA

    How to “Lower Drug Prices” Without Lowering Drug Prices

    By Rachel Sachs Yesterday, Alex Azar was sworn in as the Secretary for the Department of Health and Human Services. A key question is whether Azar will take action against high drug prices, and if…

    How to “Lower Drug Prices” Without Lowering Drug Prices

  • FDA

    Be Very, Very Concerned About What Allergan Just Did

    By Rachel Sachs Yesterday, it was announced that Allergan had transferred the ownership of the patents on its billion-dollar drug Restasis, used for the treatment of chronic dry eye, to the Saint Regis Mohawk Tribe.…

    Be Very, Very Concerned About What Allergan Just Did

  • Health Care Reform

    It’s Time To Take Responsibility, Senators

    Crossposted from the Take Care blog.  By Rachel E. Sachs Yesterday, the Senate took a key procedural vote in service of the Republicans’ never-ending quest to repeal (or at least partially repeal) the ACA. Fifty Republican senators and…

    It’s Time To Take Responsibility, Senators

  • Health Care Reform

    How to Destabilize Insurance Markets Without Really Trying

    By Rachel Sachs Cross-posted from the Take Care blog.  On Thursday, Senate Majority Leader Mitch McConnell released the latest draft of his effort to repeal the Affordable Care Act (ACA). As of last night, it…

    How to Destabilize Insurance Markets Without Really Trying

  • FDA

    New Drug Pricing Bill from Democrats Balances Innovation, Access

    By Rachel Sachs Yesterday, a group of 20 Democrats in both the House and Senate introduced the Improving Access to Affordable Prescription Drugs Act, a 129-page bill designed to lower drug costs while increasing innovation…

    New Drug Pricing Bill from Democrats Balances Innovation, Access

  • Health Law Policy

    What Happens Next for the ACA?

    Cross-posted from the Take Care blog. By Rachel Sachs and Nick Bagley In his speech after withdrawing the Republican health care bill from consideration on Friday, Speaker of the House Paul Ryan said that “Obamacare is the law…

    What Happens Next for the ACA?